Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG).
- Resource Type
- Article
- Authors
- Qi, Shu-Nan; Xu, Li-Ming; Yuan, Zhi-Yong; Wu, Tao; Zhu, Su-Yu; Shi, Mei; Su, Hang; Wang, Ying; He, Xia; Zhang, Li-Ling; Wu, Gang; Qu, Bao-Lin; Qian, Li-Ting; Hou, Xiao-Rong; Zhang, Fu-Quan; Zhang, Yu-Jing; Zhu, Yuan; Cao, Jian-Zhong; Lan, Sheng-Min; Wu, Jun-Xin
- Source
- Leukemia & Lymphoma. Nov2019, Vol. 60 Issue 11, p2669-2678. 10p.
- Subject
- *CUTANEOUS T-cell lymphoma
*TUMOR treatment
*LYMPHOMAS
*PATIENT selection
*CANCER chemotherapy
*CHINA studies
- Language
- ISSN
- 1042-8194
We evaluated the effect of primary tumor invasion (PTI) on treatment selection in 1356 patients with extranodal nasal-type NK/T cell lymphoma who received non-anthracycline-based chemotherapy from the updated dataset of China Lymphoma Collaborative Group. 760 (56.0%) patients had PTI. PTI showed most prominent effect in stage I disease, with 5-year overall survival (OS) of 83.0% in PTI-absent patients and 69.5% in PTI-present patients (p <.001). Radiotherapy ± chemotherapy achieved higher OS in PTI-absent stage I patients (approximately 85%). Either radiotherapy alone or chemotherapy alone was associated with an unfavorable OS in PTI-present patients (approximately 55%). Compared to radiotherapy alone, combined modality treatment improved OS in PTI-present patients (78.3% vs. 56.6%; p =.001) but showed similar OS in PTI-absent patients (85.3% vs. 83.3%; p =.560). These findings were confirmed in multivariate analyses. PTI was a robust prognostic factor and indicator for additional chemotherapy in stage I NKTCL patients. [ABSTRACT FROM AUTHOR]